Uterine / Endometrial
To find out more about eligibility criteria, click on the ClinicalTrials.gov links and if you are interested in participating, email the coordinator by clicking on the envelope next to the coordinator's name and notify the coordinator.
Treatment stage |
Protocol Title |
ClinicalTrials.Gov Link |
Penn Research Coordinator |
Am I Eligible? |
|---|---|---|---|---|
| Recurrent | GOG 3104: Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01) | NCT06486441 | Shavon Rochester | Eligibility Criteria |
| Recurrent | ATRN: A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral ATRN-119 in Patients with Advanced Solid Tumors | NCT04905914 | Andrea Standish, RN | Eligibility Criteria |
| Recurrent |
TPST-1495: Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors |
NCT04344795 | Jennifer Louie | Eligibility Criteria |
| Recurrent | NP-G2-044-P2-01: NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies | NCT05023486 | Shavon Rochester | |
| Recurrent | NRG-GY031: A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer | NCT05950464 | Christine Pae | Eligibility Criteria |
| Recurrent | A Phase 1/2 Study of CPI-0209 in Patients with Advanced Solid Tumors and Lymphomas | NCT04104776 | Destany Fields | Eligibility Criteria |
| Recurrent | Phase 1/2 Study of REGN5668 (MUC16 X CD28, A Costimulatory Bispecific) Administered in Combination with Cemiplimab or REGN4018 (MUC16 X CD3) | NCT04590326 | Katie Hayes, RN | Eligibility Criteria |
| Primary Radiation |
GynWPProton: Whole Pelvis Proton Radiation for Gynecologic Cancer |
NCT05758688 | Kelly Clark | Eligibility Criteria |